GlassScriptPhysician profile
Prathima Reddy
NPI 1457418816
$3,445.83
in general payments reported to CMS, 2019-2025
23 companies · $926 in 2025
The $926 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $420 · 2021: $356 · 2022: $222 · 2023: $178 · 2024: $785 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.75 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,096.29 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $503.83 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $346.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $221.72 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $172.27 | 2019-2025 | Mounjaro, Jardiance |
| Abbott Laboratories | $159.63 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $152.21 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $117.21 | 2020-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $104.10 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $90.25 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Pfizer INC. | $87.64 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.27 | 2024 | |
| Radius Health, INC. | $51.02 | 2025 | Tymlos |
| Dexcom, INC. | $45.58 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $45.44 | 2020-2025 | Nexletol |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.98 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.63 | 2025 | Xifaxan |
| Amarin Pharma, INC. | $31.86 | 2019-2020 | |
| Boston Scientific Corporation | $27.61 | 2025 | General - Erectile Dysfunction |
| Janssen Pharmaceuticals, INC | $19.54 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $18.60 | 2019 | |
| Sumitomo Pharma America, INC. | $17.58 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prathima Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.